US2012004162A1PendingUtilityA1
Methods of Treating an Overweight or Obese Subject
Est. expiryDec 4, 2028(~2.4 yrs left)· nominal 20-yr term from priority
Inventors:James E. Vath
C07D 453/02A61P 3/04C07D 303/22A61K 31/4025A61K 31/336C07D 405/12A61K 31/439C07D 303/06C07D 303/10
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure herein generally relates to methods of treating an over eight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MctAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.
Claims
exact text as granted — not AI-modified1 . A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula III:
wherein:
W is O or NR;
each R is, independently hydrogen or a C 1 -C 4 -alkyl;
Q is hydrogen, a linear, branched or cyclic C 1 -C 6 -alkyl; or aryl;
R 1 is hydroxy, C 1 -C 4 -alkoxy or halogen; and
Z is —C(O)— or C 1 -C 4 -alkylene-C(O)—; and P is NHR, OR, or a peptide consisting of 1 to about 100 amino acid residues attached to Z at the N-terminus;
or Z is alkylene-O or alkylene-NR; and P is hydrogen or peptide comprising 1 to 100 amino acid residues attached to Z at the C-terminus;
or a pharmaceutically acceptable salt, ester, or prodrug thereof.
2 . A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprises a compound selected from the group consisting of:
3 . The method of claim 1 , wherein the subject has a Body Mass Index measurement selected from the group consisting of: at least about 25 kg/m 2 , at least about 30 kg/m 2 , and at least about 40 kg/m 2 .
4 . The method of claim 1 , wherein the pharmaceutical composition is administered non-parenterally.
5 . The method of claim 1 , wherein the pharmaceutical composition is administered orally, buccally, sublingually, transdermally, via inhalation, or rectally.
6 . The method of claim 1 , wherein the pharmaceutical composition is administered parenterally.
7 . The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously.
8 . The method of claim 1 , wherein administration results in decreased body fat and a substantial maintenance of muscle mass in the subject.
9 . The method of claim 1 , wherein upon administration, fat oxidation is enhanced as compared to a subject on a restricted food intake diet alone.
10 . The method of claim 1 , wherein substantially no loss of new blood vessels in fat deposits occur as compared to a subject being treated for obesity using an energy restricted diet alone.
11 .- 15 . (canceled)
16 . A method of decreasing body fat in an overweight or obese subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula III to said subject resulting in body fat reduction, and wherein said subject substantially maintains muscle mass during the body fat reduction.
17 . The method of claim 16 , wherein the subject retains substantially more muscle mass as compared to body fat reduction in a subject using an energy restricted diet alone.
18 .- 19 . (canceled)
20 . A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising the compoundCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.